Ad is loading...
ALLO
Price
$2.21
Change
+$0.10 (+4.74%)
Updated
Nov 22 closing price
95 days until earnings call
ATAI
Price
$1.61
Change
+$0.09 (+5.92%)
Updated
Nov 22 closing price
124 days until earnings call
Ad is loading...

ALLO vs ATAI

Header iconALLO vs ATAI Comparison
Open Charts ALLO vs ATAIBanner chart's image
Allogene Therapeutics
Price$2.21
Change+$0.10 (+4.74%)
Volume$1.46M
CapitalizationN/A
ATAI Life Sciences
Price$1.61
Change+$0.09 (+5.92%)
Volume$2.12M
CapitalizationN/A
ALLO vs ATAI Comparison Chart
Loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ATAI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ALLO vs. ATAI commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Hold and ATAI is a StrongBuy.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (ALLO: $2.21 vs. ATAI: $1.61)
Brand notoriety: ALLO and ATAI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 65% vs. ATAI: 158%
Market capitalization -- ALLO: $463.38M vs. ATAI: $270.16M
ALLO [@Biotechnology] is valued at $463.38M. ATAI’s [@Biotechnology] market capitalization is $270.16M. The market cap for tickers in the [@Biotechnology] industry ranges from $450.11B to $0. The average market capitalization across the [@Biotechnology] industry is $2.6B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileATAI’s FA Score has 1 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • ATAI’s FA Score: 1 green, 4 red.
According to our system of comparison, ATAI is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 5 TA indicator(s) are bullish while ATAI’s TA Score has 6 bullish TA indicator(s).

  • ALLO’s TA Score: 5 bullish, 5 bearish.
  • ATAI’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, ATAI is a better buy in the short-term than ALLO.

Price Growth

ALLO (@Biotechnology) experienced а -2.64% price change this week, while ATAI (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.38%. For the same industry, the average monthly price growth was -4.87%, and the average quarterly price growth was +4.35%.

Reported Earning Dates

ALLO is expected to report earnings on Feb 26, 2025.

ATAI is expected to report earnings on Mar 27, 2025.

Industries' Descriptions

@Biotechnology (+2.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALLO($463M) has a higher market cap than ATAI($270M). ATAI YTD gains are higher at: 14.184 vs. ALLO (-31.153). ATAI has higher annual earnings (EBITDA): -124.33M vs. ALLO (-256.67M). ALLO has more cash in the bank: 292M vs. ATAI (85.9M). ATAI has less debt than ALLO: ATAI (23.8M) vs ALLO (85.1M). ATAI has higher revenues than ALLO: ATAI (331K) vs ALLO (43K).
ALLOATAIALLO / ATAI
Capitalization463M270M171%
EBITDA-256.67M-124.33M206%
Gain YTD-31.15314.184-220%
P/E RatioN/AN/A-
Revenue43K331K13%
Total Cash292M85.9M340%
Total Debt85.1M23.8M358%
FUNDAMENTALS RATINGS
ALLO vs ATAI: Fundamental Ratings
ALLO
ATAI
OUTLOOK RATING
1..100
5823
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
80
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
8542
P/E GROWTH RATING
1..100
10022
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATAI's Valuation (80) in the Miscellaneous Commercial Services industry is in the same range as ALLO (97) in the Biotechnology industry. This means that ATAI’s stock grew similarly to ALLO’s over the last 12 months.

ATAI's Profit vs Risk Rating (100) in the Miscellaneous Commercial Services industry is in the same range as ALLO (100) in the Biotechnology industry. This means that ATAI’s stock grew similarly to ALLO’s over the last 12 months.

ALLO's SMR Rating (97) in the Biotechnology industry is in the same range as ATAI (98) in the Miscellaneous Commercial Services industry. This means that ALLO’s stock grew similarly to ATAI’s over the last 12 months.

ATAI's Price Growth Rating (42) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for ALLO (85) in the Biotechnology industry. This means that ATAI’s stock grew somewhat faster than ALLO’s over the last 12 months.

ATAI's P/E Growth Rating (22) in the Miscellaneous Commercial Services industry is significantly better than the same rating for ALLO (100) in the Biotechnology industry. This means that ATAI’s stock grew significantly faster than ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOATAI
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 5 days ago
78%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Ad is loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ATAI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYBKX100.241.93
+1.96%
Rydex Banking A
CECFX29.870.07
+0.25%
Columbia Large Cap Enhanced Core Adv
TWSIX129.260.05
+0.04%
American Century Select I
DLDCX44.27N/A
N/A
BNY Mellon Natural Resources C
TLGYX59.04-0.04
-0.07%
Touchstone Large Company Growth Y

ALLO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with FATE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
+4.74%
FATE - ALLO
56%
Loosely correlated
+10.63%
NTLA - ALLO
55%
Loosely correlated
+3.62%
BEAM - ALLO
55%
Loosely correlated
+6.23%
CRSP - ALLO
54%
Loosely correlated
+3.43%
CRBU - ALLO
53%
Loosely correlated
+2.02%
More

ATAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATAI has been loosely correlated with FATE. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ATAI jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATAI
1D Price
Change %
ATAI100%
+5.92%
FATE - ATAI
48%
Loosely correlated
+10.63%
NTLA - ATAI
47%
Loosely correlated
+3.62%
ABCL - ATAI
46%
Loosely correlated
+1.47%
COUR - ATAI
45%
Loosely correlated
+1.86%
ALLO - ATAI
45%
Loosely correlated
+4.74%
More